TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sacral Nerve Stimulation in Improving Bladder Function After Acute Traumatic Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Ability to implant device less than 12 weeks post-SCI~* Presence of acute SCI at or above T12~* ASIA Scale A or B~* Expectation to perform CIC personally or have caretaker perform CIC~Exclusion Criteria:~* Inability to perform CIC~* Pre-existing SCI~* Pre-existing progressive neurological disorder~* Autonomic dysreflexia~* Prior sacral back surgery~* Posterior pelvic fracture with distortion of the sacroiliac joint~* Prior urethral sphincter or bladder dysfunction~* Chronic urinary tract infections prior to SCI~* Pregnancy at the time of enrollment~* Presence of coagulation disorder or need for anticoagulation that they cannot be stopped temporarily for procedure~* Any significant co-morbidity or illness that would preclude their participation or increase the risk to them having a surgical procedure~* Active untreated infection~* Traumatic injury to the genitourinary system~* Prior pelvic radiation, bladder cancer or other surgical procedure to the bladder that would effect baseline bladder physiology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sacral neuromodulation (Type: EXPERIMENTAL): Bilateral sacral neuromodulation will start within 3 months of spinal cord injury, as well as standard neurogenic bladder care.
- Standard care (Type: NO_INTERVENTION): Patients will receive standard neurogenic bladder care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and sign a written informed consent form~* Receiving Atripla continuously for \>12 weeks preceding the screening visit~* Plasma HIV-1 RNA levels (at least in two measurements) \<50 copies/mL for \>8 weeks prior to the screening visit and at the screening visit~* Atripla or Truvada + Efavirenz was the first antiretroviral regimen and no HIV-1 RNA \> 50 copies/mL measured at two consecutive time points after first achieving HIV RNA \<50 copies/mL~* Had a genotype prior to starting study drugs and no known resistance to any of the study drugs~* Normal ECG~* Hepatic transaminase (AST and ALT) \<5 X upper limit of normal (ULN)~* Total bilirubin \<1.5 mg/dL~* eGFR \> 60 mL/min~* Neutrophil count \> 1000/mm3, platelets \>50,000/mm3. Haemoglobin \> 8.5 g/dL~* Age \> 18~* Males and Females of childbearing potential must have agreed to utilize highly effective contraception methods (two separate forms of contraception, one of which must be an effective barrier method, or be nonheterosexually active, practice sexual abstinence, or have a vasectomized partner) from screening throughout the duration of the study period and for 60 days following the last dose of study drug.~Exclusion Criteria:~* Subjects with known allergy to one of the study drugs~* AIDS defining event diagnosed within 21 days prior to screening~* Females who are pregnant or breast feeding~* Acute hepatitis diagnosed within 21 days prior to screening~* Subjects receiving drug treatment for HCV or subjects anticipated to receive treatment for HCV during the course of the study~* Implanted defibrillator or pacemaker~* Current alcohol or drug abuse judged by the investigator to potentially interfere with subject adherence~* Participation in another interventional trial~* Ongoing therapy or anticipated need to initiate drugs during the study that are contraindicated or not recommended for use with study drugs (Carbamazepine, Dexamethasone, Esomeprazole, Fosphenytoin, Lansoprazole, Omeprazole, Oxcarbazepine, Pantoprazole, Phenobarbital, Phenytoin, Piperaquine, Primnidone, Rabeprazole, Rifabutin, Rifampin, Rifapentine, St John's Wort~* Any Severe Psychiatric disease that judged by the investigator to potentially interfere with subject adherence to protocol or to drugs or that may interfere with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eviplera (complera) (Type: EXPERIMENTAL): Tab eviplera QD
- atripla (Type: ACTIVE_COMPARATOR): Tab Atripla QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Schizophrenic Patients in Integrated Care

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with baseline SWN-K \<=70~* Provision of signed informed consent~* Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points~Exclusion Criteria:~* Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS~* Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation~* Patients who pose an imminent risk of suicide or danger to self or others

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Quetiapine XR Alone (Type: EXPERIMENTAL): Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
- Quetiapine XR With Integrated Care Program (ICP) (Type: EXPERIMENTAL): Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Penicillin Challenge and Allergy De-labeling in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients in the pediatric emergency department who are 2-17 yo and labeled as penicillin-allergic (including amoxicillin or other penicillin allergies)~2. Patients at low risk of anaphylaxis as determined by the study questionnaire~3. Patients who would normally be prescribed amoxicillin, amoxicillin-clavulanate or another penicillin for their current bacterial infection, including otitis media, Group A Streptococcal pharyngitis, pneumonia. sinusitis, dog and cat bite wounds, regimens for Helicobacter pylori eradication, or other acute infections deemed susceptible.~4. Patients who are interested in participating~5. Patients who have an acceptable surrogate to give consent on the subject's behalf~6. Patients whose surrogate (parent/caregiver) speaks English or Spanish~Exclusion Criteria:~1. Patients who are uninterested in participating, or their parents/caregivers are not interested in having them participate~2. Patients who have multiple drug allergies

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Oral Challenge (Type: EXPERIMENTAL): Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to oral amoxicillin 500 mg challenge.
- No Oral Challenge (Type: NO_INTERVENTION): Patients will be screened for high vs. low risk of penicillin allergy. Low risk patients will be randomized to no oral amoxicillin 500 mg challenge..

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* evidence of subacute or chronic supratentorial subdural hematoma by CT (computerized tomography) scan or MRI (magnetic resonance imaging)~* classified between 0 and 2 using the Markwalder grading scale~Exclusion Criteria:~* contraindications or intolerance to corticosteroid therapy~* patients already undergoing steroid treatment for any other indication~* previous neurological surgery up to one year prior to being considered for the study~* concomitant cerebral pathology of neoplastic or presumed infectious origin~* anticoagulant therapy that could not be stopped for 6 months~* refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexamethasone (Type: EXPERIMENTAL): Participants allocated to the treatment group received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
- Control (Type: PLACEBO_COMPARATOR): Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate-severe COPD (Global inititiative for chronic Obstructive Lung Disease, GOLD, 2003 definition)~* Smoking history of at least 10 pack-years~Exclusion Criteria:~* Any significant co-morbid disease~* Use of any maintenance therapy except short acting bronchodilators

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 18 years or older~* Histologically confirmed primary DLBCL of any stage~* Refractory to the last treatment regimen~* Previously treated with the following treatment regimens:~* Anthracycline-based combination chemotherapy with rituximab~* Second-line combination chemotherapy~* Autologous BMT if the subject was eligible and did not refuse the procedure~* At least one measurable lesion defined as \> 1.5 cm in the longest diameter~* No known central nervous system involvement~* ECOG performance status \< 2~* Life expectancy \> 12 weeks~* If female, non-pregnant and non-lactating~* IRB-approved consent and HIPAA Authorization~Exclusion Criteria:~* Transformed, composite or discordant lymphoma~* Therapy for lymphoma within 21 days prior to the first dose of YM155~* Within 4 weeks of the screening FDG-PET scan, receipt of the following:~* Radiation therapy~* Surgical procedures (except biopsies and central catheter / port placement)~* Active infection (bloodstream or deep tissue)~* Inadequate marrow, hepatic and/or renal function~* Serum creatinine \> 1.5 x ULN or calculated serum creatinine clearance \< 60 mL/min~* Absolute Neutrophil Count (ANC) \< 750/mm3~* Platelet \< 50,000/mm3~* Alanine Transaminase (ALT) and Aspartate Transaminase (AST) \> 2.5 x ULN; \> 5 x ULN if secondary to liver metastases~* Treated with \> 3 prior treatment regimens. The following should be considered:~* Planned maintenance therapy should be considered as part of the previous treatment regimen~* Any preparative treatment (salvage chemotherapy, high-dose chemotherapy, radiation therapy, etc.) should be included with the autologous BMT or PBSCT as one treatment~* Prior allogeneic BMT or PBSCT~* Previously treated with YM155~* Other investigational therapy or procedures within 28 days~* Known HIV, hepatitis B surface antigen, or hepatitis C antibody~* Other malignancy requiring treatment within 2 years~* Significant and/or uncontrolled cardiac, renal, hepatic, or other systemic disorders or significant psychological conditions that in the Investigator's judgment would jeopardize subject enrollment or compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally recurrent or metastatic TNBC, defined as ER/PR \<1%, HER2 0-1+, or 2+ with negative FISH~* Measurable disease per RECIST version 1.1~* ECOG performance status of 0 or 1~* Confirmed available archival tumor tissue.~Exclusion Criteria:~* More than 1 prior systemic chemotherapy for treatment of locally recurrent or metastatic breast cancer (neoadjuvant and adjuvant therapy is allowed provided the subject did not progress within 12 months of taxane based therapy~* Prior treatment with VEGF pathway targeted agent~* Major surgery within 4 weeks or minor surgery or radiotherapy within 2 weeks of first dose of study drug~* Known history of central nervous system metastasis (subjects with previously treated (radiotherapy or surgery) brain metastasis that have been stable off steroids or enzyme-inducing antiepileptic drugs for at least 3 months following prior treatment may be enrolled)~* Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders~* Significant serum chemistry or urinalysis abnormalities~* Significant cardiovascular disease, including: uncontrolled hypertension; myocardial infarction or unstable angina within 6 months prior to administration of first dose of study drug; and symptomatic left ventricular dysfunction or baseline left ventricular ejection fraction (LVEF) by multigated acquisition scan (MUGA) or ECHO.~* Severe peripheral neuropathy ≥ Grade 2~* Currently active second primary malignancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo in combination with paclitaxel (Type: ACTIVE_COMPARATOR): Placebo orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).
- Tivo in combination with paclitaxel (Type: EXPERIMENTAL): 1.5 mg tivozanib hydrochloride orally once daily on a 3 weeks on/1 week off schedule with 90 mg/m2 of paclitaxel administered intravenously 3 weeks on (Day 1, Day 8 and Day 15)/1 week off (4 weeks = 1 Cycle).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-pharmacological Analgesia During Heel Prick

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy term neonates (37-41+6 weeks of gestation) confirmed through a routine physical exam during the first 24h of life~* Wish to breastfeed~* Absence of feeding during the previous 60 minutes.~Exclusion Criteria:~* Maternal use of opioids.~* Birth in general anesthesia.~* Artificial feeding.~* Previous capillar or venous sampling.~* Previous admission to the neonatal unit.

- Gender: ALL
- Minimum Age: 37 Weeks
- Maximum Age: 41 Weeks
- Healthy Volunteers: t

Study Arms:
- Breastfeeding + skin-to-skin contact (Type: EXPERIMENTAL): In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; breastfeeding (BF) was started at least 5 minutes before heel lance and maintained during sampling
- Sucrose + skin-to-skin contact (Type: EXPERIMENTAL): In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance.
- Skin-to-skin contact (Type: EXPERIMENTAL): In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given.
- Sucrose (Type: ACTIVE_COMPARATOR): In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for COVID-19 Treatment in Outpatients Nationwide

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evidence of a positive SARS-CoV-2 test and test results received within the previous seven days~* Not currently hospitalized~* Willing and able to receive study drug by mail~* Willing and able to do the study questionnaires at baseline, day 3, 7, 14, 21 days via email or over the phone~* No known allergy or other contraindication to macrolides~* Age 18 years or older at the time of enrollment~* No known history of prolongation of the QT interval (eg. History of torsades de pointes, congenital long QT syndrome, bradyarrhthmia)~* No recent use of hydroxychloroquine within the past 7 days for participants \>55 years of age~* Not currently taking nelfinavir or warfarin (Coumadin)~* Provision of informed consent~* Not currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): 1.2g of oral azithromycin
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age~* Subject is a suitable candidate for aortocoronary bypass (CABG) procedure. Subjects undergoing CABG procedure without the use of coronary artery bypass (off pump) are preferred. However, subjects requiring coronary artery bypass will not be excluded from the study~* Female subjects of childbearing potential must have a documented negative serum pregnancy test within 2 days before the CABG procedure~* Subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits~* Subject has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board/Ethics Committee of the respective clinical site.~Exclusion Criteria:~* Subject will have valve replacement or repair during CABG procedure~* Subject has a poor quality donor vessel (poor or turbulent flow, varicose)~* Subject has a known left ventricular ejection fraction of \<35%~* Subject has had a percutaneous coronary intervention (PCI) for coronary artery disease treatment 30 days prior to CABG~* Subject has a PCI planned during the 30 days immediately following the CABG procedure~* Subject has chronic atrial fibrillation~* Subject has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, or sensitivity to contrast media which cannot be adequately pre-medicated~* Subject has chronic renal insufficiency (i.e., serum creatinine \>180 mmol/L) or co-morbid illness which precludes follow-up angiography~* Subject has history of a stroke or transient ischemic attack within the prior 6 months~* Subject has an active peptic ulcer or has had clinically significant upper or lower GI bleeding within the prior 6 months~* Subject has a history of a bleeding diathesis or coagulopathy or will refuse blood transfusions~* Subject has a non-cardiac illness imposing substantial operative mortality~* Subject has a concurrent medical condition resulting in a life expectancy of less than 3 years~* Subject is currently participating in an investigational drug or another device study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy